Drug Profile
Research programme: PASylated cytokine - XL-protein GmbH
Latest Information Update: 09 Aug 2016
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Developer International Biotechnology Center Generium; XL-protein GmbH
- Class Cytokines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 09 Aug 2016 No recent reports on development identified for Undefined indication in Germany, Russia, Commonwealth of Independent States (unspecified route)